Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus: A Multicenter, Randomized Controlled Trial

Autor: Midas B. Mulder, PharmD, Bart van Hoek, MD, PhD, Wojtek G. Polak, MD, PhD, Ian P.J. Alwayn, MD, PhD, Brenda C.M. de Winter, PharmD, PhD, Sarwa Darwish Murad, MD, PhD, Elke Verhey-Hart, BSc, Lara Elshove, MSc, Nicole S. Erler, Dipl-Stat, PhD, Dennis A. Hesselink, MD, PhD, Caroline M. den Hoed, MD, PhD, Herold J. Metselaar, MD, PhD

Publikováno v: Transplantation Direct, Vol 10, Iss 4, p e1612 (2024)

Background. The aim of this open-label, multicenter, randomized controlled study was to investigate whether the life cycle pharma (LCP)-tacrolimus compared with the extended-release (ER)-tacrolimus formulation results in a difference in the prevalenc

Externí odkaz: https://doaj.org/article/e000db20ac504b629c8bfe70cc940d02

Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up

Autor: Xun Qi, Adrian Streinu-Cercel, Heng Chi, Fehmi Tabak, Qing Xie, Mircea Diculescu, Margo J. H. van Campenhout, Elke Verhey, Harry L.A. Janssen, Willem P. Brouwer, Bettina E. Hansen, Hendrik W. Reesink, Włodzimierz Mazur, Rob J. de Knegt, Krzysztof Simon, Ningping Zhang, Meral Akdogan, J. Wang, S. Guo, Ramazan Idilman

Publikováno v: Journal of viral hepatitis, 26(1), 109-117. Wiley-Blackwell
Journal of Viral Hepatitis, 26(1), 109-117. Wiley-Blackwell Publishing Ltd

Addition of peginterferon alpha (PEG-IFN add-on) to entecavir (ETV) treatment after a short lead-in phase results in more response than ETV monotherapy in HBeAg-positive chronic hepatitis B infection (CHB). This study is the first to assess long-term

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2add2b6196a6377758f5b7c0a3a713e1
https://doi.org/10.1111/jvh.12997

Genome Wide Association Study Identifies Genetic Variants Associated with Early and Sustained Response to (Peg)Interferon in Chronic Hepatitis B Patients: The GIANT-B Study

Autor: Willem Pieter Brouwer, Henry L. Y. Chan, Pietro Lampertico, Jinlin Hou, Pisit Tangkijvanich, Hendrik W. Reesink, Wenhong Zhang, Alessandra Mangia, Tawesak Tanwandee, Giuseppe Montalto, Kris Simon, Necati Ormeci, Liang Chen, Fehmi Tabak, Fulya Gunsar, Robert Flisiak, Peter Ferenci, Meral Akdogan, Filiz Akyuz, Nattiya Hirankarn, Louis Jansen, Vincent Wai-Sun Wong, Roberta Soffredini, Xieer Liang, Shalom Chen, Zwier M. A. Groothuismink, Rosanna Santoro, Jerzy Jaroszewicz, Resat Ozaras, Karin Kozbial, Mayur Brahmania, Qing Xie, Watcharasak Chotiyaputta, Xun Qi, Monika Pazgan-Simon, Erkin Oztas, Elke Verhey, Noé R. Montanari, Jian Sun, Bettina E. Hansen, Andre Boonstra, Harry L. A. Janssen, GIANT-B Global Consortium

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27a93ec944f7f0632815601b01b9a4a0
https://doi.org/10.2139/ssrn.3224898

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

Autor: Elke Verhey, C. Janneke van der Woude, Bettina E. Hansen, Hendrik M. van Dullemen, Ad A. van Bodegraven, Maurice G. Russel, Pieter Dewint, Bas Oldenburg, Marieke Pierik, Cyriel I J Ponsioen, Daniel W. Hommes

Publikováno v: Gut, 63(2), 292-299. BMJ Publishing Group
Gut, 63(2), 292-299
Gut, 63(2), 292-299. BMJ PUBLISHING GROUP
Dewint, P, Hansen, B E, Verhey, E, Oldenburg, B, Hommes, D W, Pierik, M, Ponsioen, C I J, van Dullemen, H M, Russel, M, van Bodegraven, A A & van der Woude, C J 2014, ' Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI) ', Gut, vol. 63, no. 2, pp. 292-299 . https://doi.org/10.1136/gutjnl-2013-304488

Objective To assess whether a combination of adalimumab and ciprofloxacin is superior to adalimumab alone in the treatment of perianal fistulising Crohn's disease (CD).Design Randomised, double-blind, placebo controlled trial in eight Dutch hospitals

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad612feec66cc03564e5096f564d3e3
https://doi.org/10.1136/gutjnl-2013-304488

Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon alpha-2a: progressive decrease in hepatitis B surface antigen in responders

Autor: Vincent, Rijckborst, Peter, Ferenci, Meral, Akdogan, Binnur, Pinarbasi, Martijn J, ter Borg, Krzysztof, Simon, Robert, Flisiak, Ulus S, Akarca, Maria, Raptopoulou-Gigi, Elke, Verhey, Anneke J, van Vuuren, Charles A, Boucher, Bettina E, Hansen, Harry L A, Janssen, F, Tabak

Publikováno v: European Journal of Gastroenterology & Hepatology, 24(9), 1012-1019. Lippincott Williams & Wilkins

OBJECTIVE Peginterferon (PEG-IFN) is considered as a first-line treatment option for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. We aimed to evaluate the long-term response to PEG-IFN in HBeAg-negative patients. METHODS All patients e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a93d4a67163709a66189e1ecd8d4995b
https://hdl.handle.net/1765/39042